Phase II trial of weekly erlotinib dosing to reduce duodenal polyp burden associated with familial adenomatous polyposis
Sign Up to like & getrecommendations! Published in 2022 at "Gut"
DOI: 10.1136/gutjnl-2021-326532
Abstract: Importance Patients with familial adenomatous polyposis (FAP) are at markedly increased risk for duodenal adenomas and cancer. Combination sulindac and erlotinib was previously shown to reduce duodenal polyp burden but was associated with a relatively… read more here.
Keywords: duodenal polyp; polyp burden; intervention; polyposis ... See more keywords
Well Differentiated Liposarcoma Presenting as a Duodenal Polyp: A Case Report and Review of the Literature
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Surgical Pathology"
DOI: 10.1177/10668969221099628
Abstract: Liposarcoma is the most common malignant soft tissue tumour in adults occurring predominantly in the retroperitoneum and extremities but very rarely within the gastrointestinal tract. We report on a 77-year-old gentleman who presented with a… read more here.
Keywords: duodenal polyp; differentiated liposarcoma; report; polyp ... See more keywords